Fintel reports that on September 29, 2023, JP Morgan maintained coverage of Amicus Therapeutics (NASDAQ:FOLD) with a Overweight recommendation.
Analyst Price Forecast Suggests 37.57% Upside
As of August 31, 2023, the average one-year price target for Amicus Therapeutics is 16.73. The forecasts range from a low of 12.12 to a high of $21.00. The average price target represents an increase of 37.57% from its latest reported closing price of 12.16.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Amicus Therapeutics is 451MM, an increase of 28.72%. The projected annual non-GAAP EPS is -0.20.
What is the Fund Sentiment?
There are 465 funds or institutions reporting positions in Amicus Therapeutics. This is a decrease of 11 owner(s) or 2.31% in the last quarter. Average portfolio weight of all funds dedicated to FOLD is 0.28%, an increase of 4.33%. Total shares owned by institutions increased in the last three months by 3.58% to 339,200K shares. 
The put/call ratio of FOLD is 0.69, indicating a bullish outlook.
What are Other Shareholders Doing?
Perceptive Advisors holds 27,663K shares representing 9.63% ownership of the company. No change in the last quarter.
Avoro Capital Advisors holds 27,400K shares representing 9.54% ownership of the company. In it's prior filing, the firm reported owning 27,300K shares, representing an increase of 0.36%. The firm increased its portfolio allocation in FOLD by 4.02% over the last quarter.
Redmile Group holds 19,567K shares representing 6.81% ownership of the company. In it's prior filing, the firm reported owning 18,347K shares, representing an increase of 6.24%. The firm increased its portfolio allocation in FOLD by 6.84% over the last quarter.
Janus Henderson Group holds 14,924K shares representing 5.20% ownership of the company. In it's prior filing, the firm reported owning 13,610K shares, representing an increase of 8.80%. The firm increased its portfolio allocation in FOLD by 15.63% over the last quarter.
Jpmorgan Chase holds 13,442K shares representing 4.68% ownership of the company. In it's prior filing, the firm reported owning 13,733K shares, representing a decrease of 2.17%. The firm increased its portfolio allocation in FOLD by 687.50% over the last quarter.
Amicus Therapeutics Background Information
(This description is provided by the company.)
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
